All Outputs (2)

Selected derivatives of erythromycin B- in silico and anti-malarial studies (2021)
Journal Article
Bhadra, P., Magwaza, R., Nirmalan, N., Freeman, S., Barber, J., & Arsic, B. (2021). Selected derivatives of erythromycin B- in silico and anti-malarial studies. Materials, 14(22), e6980. https://doi.org/10.3390/ma14226980

Erythromycin A is an established anti-bacterial agent against Gram-positive bacteria, but it is unstable to acid. This led to an evaluation of erythromycin B and its derivatives because these have improved acid stability. These compounds were investi... Read More about Selected derivatives of erythromycin B- in silico and anti-malarial studies.

Improved biopharmaceutical attributes of lumefantrine using choline mimicking drug delivery system : preclinical investigation on NK-65 P.berghei murine model (2021)
Journal Article
Kaur, R., Gorki, V., Katare, O., Dhingra, N., Chauhan, M., Kaur, R., …Singh, B. (2021). Improved biopharmaceutical attributes of lumefantrine using choline mimicking drug delivery system : preclinical investigation on NK-65 P.berghei murine model. Expert Opinion on Drug Delivery, 18(10), 1533-1552. https://doi.org/10.1080/17425247.2021.1946512

Background Lumefantrine (LMF) is first-line antimalarial drug, possesses activity against almost all human malarial parasites, but the in vivo activity of this molecule gets thwarted due to its low and inconsistent oral bioavailability (i.e. 4–12%)... Read More about Improved biopharmaceutical attributes of lumefantrine using choline mimicking drug delivery system : preclinical investigation on NK-65 P.berghei murine model.